Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Abstract: Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective c...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576441081921536 |
|---|---|
| author | Jessy Xinyi Han Min Jung Koh Leora Boussi Mark Sorial Sean M. McCabe Luke Peng Shambhavi Singh Ijeoma Julie Eche-Ugwu Judith Gabler Maria J. Fernandez Turizo Caroline T. MacVicar Aditya Garg Alexander Disciullo Kusha Chopra Alexandra Lenart Emmanuel Nwodo Jeffrey Barnes Min Ji Koh Eliana Miranda Carlos Chiattone Robert Stuver Steven M. Horwitz Mwanasha Merrill Eric Jacobsen Martina Manni Monica Civallero Tetiana Skrypets Athina Lymboussaki Massimo Federico Yuri Kim Jin Seok Kim Jae Yong Cho Thomas Eipe Tanuja Shet Epari Sridhar Alok Shetty Saswata Saha Hasmukh Jain Manju Sengar Carrie Van Der Weyden Henry Miles Prince Ramzi Hamouche Tinatin Murdashvili Francine Foss Marianna Gentilini Beatrice Casadei Pier Luigi Zinzani Takeshi Okatani Noriaki Yoshida Sang Eun Yoon Won-Seog Kim Girisha Panchoo Zainab Mohamed Estelle Verburgh Jackielyn Cuenca Alturas Mubarak Al-Mansour Josie Ford Maria Elena Cabrera Amy Ku Govind Bhagat Helen Ma Ahmed Sawas Khyati Maulik Kariya Makoto Iwasaki Forum Bhanushali Owen A. O’Connor Enrica Marchi Changyu Shen Devavrat Shah Salvia Jain |
| author_facet | Jessy Xinyi Han Min Jung Koh Leora Boussi Mark Sorial Sean M. McCabe Luke Peng Shambhavi Singh Ijeoma Julie Eche-Ugwu Judith Gabler Maria J. Fernandez Turizo Caroline T. MacVicar Aditya Garg Alexander Disciullo Kusha Chopra Alexandra Lenart Emmanuel Nwodo Jeffrey Barnes Min Ji Koh Eliana Miranda Carlos Chiattone Robert Stuver Steven M. Horwitz Mwanasha Merrill Eric Jacobsen Martina Manni Monica Civallero Tetiana Skrypets Athina Lymboussaki Massimo Federico Yuri Kim Jin Seok Kim Jae Yong Cho Thomas Eipe Tanuja Shet Epari Sridhar Alok Shetty Saswata Saha Hasmukh Jain Manju Sengar Carrie Van Der Weyden Henry Miles Prince Ramzi Hamouche Tinatin Murdashvili Francine Foss Marianna Gentilini Beatrice Casadei Pier Luigi Zinzani Takeshi Okatani Noriaki Yoshida Sang Eun Yoon Won-Seog Kim Girisha Panchoo Zainab Mohamed Estelle Verburgh Jackielyn Cuenca Alturas Mubarak Al-Mansour Josie Ford Maria Elena Cabrera Amy Ku Govind Bhagat Helen Ma Ahmed Sawas Khyati Maulik Kariya Makoto Iwasaki Forum Bhanushali Owen A. O’Connor Enrica Marchi Changyu Shen Devavrat Shah Salvia Jain |
| author_sort | Jessy Xinyi Han |
| collection | DOAJ |
| description | Abstract: Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a ''novel'' single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL. |
| format | Article |
| id | doaj-art-d45e36941b914cbca5e5ddceb4700774 |
| institution | Kabale University |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-d45e36941b914cbca5e5ddceb47007742025-01-31T05:12:09ZengElsevierBlood Advances2473-95292025-02-0193583602Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han0Min Jung Koh1Leora Boussi2Mark Sorial3Sean M. McCabe4Luke Peng5Shambhavi Singh6Ijeoma Julie Eche-Ugwu7Judith Gabler8Maria J. Fernandez Turizo9Caroline T. MacVicar10Aditya Garg11Alexander Disciullo12Kusha Chopra13Alexandra Lenart14Emmanuel Nwodo15Jeffrey Barnes16Min Ji Koh17Eliana Miranda18Carlos Chiattone19Robert Stuver20Steven M. Horwitz21Mwanasha Merrill22Eric Jacobsen23Martina Manni24Monica Civallero25Tetiana Skrypets26Athina Lymboussaki27Massimo Federico28Yuri Kim29Jin Seok Kim30Jae Yong Cho31Thomas Eipe32Tanuja Shet33Epari Sridhar34Alok Shetty35Saswata Saha36Hasmukh Jain37Manju Sengar38Carrie Van Der Weyden39Henry Miles Prince40Ramzi Hamouche41Tinatin Murdashvili42Francine Foss43Marianna Gentilini44Beatrice Casadei45Pier Luigi Zinzani46Takeshi Okatani47Noriaki Yoshida48Sang Eun Yoon49Won-Seog Kim50Girisha Panchoo51Zainab Mohamed52Estelle Verburgh53Jackielyn Cuenca Alturas54Mubarak Al-Mansour55Josie Ford56Maria Elena Cabrera57Amy Ku58Govind Bhagat59Helen Ma60Ahmed Sawas61Khyati Maulik Kariya62Makoto Iwasaki63Forum Bhanushali64Owen A. O’Connor65Enrica Marchi66Changyu Shen67Devavrat Shah68Salvia Jain69Massachusetts Institute of Technology, Cambridge, MAGeorgetown University School of Medicine, Washington, DCDepartment of Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NYMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MACollege of Science, Northeastern University, Boston, MADepartment of Medicine, Massachusetts General Hospital, Boston, MADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MADepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MAGeorgetown University School of Medicine, Washington, DC; Massachusetts General Hospital Cancer Center, Boston, MAUniversity of Campinas-UNICAMP, Hematology and Hemotherapy Center, Statistical and Data Center, Sao Paulo, BrazilDepartment of Medicine, Santa Casa Medicine School, Sao Paulo, BrazilLymphoma Service, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NYLymphoma Service, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MADepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, ItalyCHIMOMO Department, University of Modena and Reggio Emilia, Modena, ItalyHematology and Cell Therapy Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, ItalyDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, ItalyCHIMOMO Department, University of Modena and Reggio Emilia, Modena, ItalyDepartment of Medicine, Gangnam Severance Hospital, Yonsei University School of Medicine, Seoul, Republic of KoreaDepartment of Medicine, Gangnam Severance Hospital, Yonsei University School of Medicine, Seoul, Republic of KoreaDepartment of Medicine, Gangnam Severance Hospital, Yonsei University School of Medicine, Seoul, Republic of KoreaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaTata Memorial Centre, Homi Bhabha National Institute, Mumbai, IndiaSir Peter MacCallum Department of Hematology and Oncology, The University of Melbourne, Parkville, AustraliaSir Peter MacCallum Department of Hematology and Oncology, The University of Melbourne, Parkville, AustraliaDepartment of Hematology, Yale Cancer Center, New Haven, CTDepartment of Hematology, Yale Cancer Center, New Haven, CTDepartment of Hematology, Yale Cancer Center, New Haven, CTIstituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli,” Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, ItalyIstituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli,” Bologna, ItalyIstituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli,” Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, ItalyDepartment of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, JapanDepartment of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, JapanDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Pathology, University of Cape Town and Groote Schuur Hospital, Cape Town, South AfricaDepartment of Radiation Oncology, University of Cape Town and Groote Schuur Hospital, Cape Town, South AfricaDepartment of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South AfricaDepartment of Medicine, King Abdulaziz Medical City, Jeddah, Saudi ArabiaDepartment of Medicine, King Abdulaziz Medical City, Jeddah, Saudi ArabiaMassachusetts General Hospital Cancer Center, Boston, MAHematology Department, Hospital del Salvador, University of Chile, Santiago, ChileColumbia University Irving Medical Center, New York, NYColumbia University Irving Medical Center, New York, NYUniversity of California, Irvine, VA Long Beach Health System, Long Beach, CAColumbia University Irving Medical Center, New York, NYMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAMassachusetts General Hospital Cancer Center, Boston, MAProgram for T-Cell Lymphoma Research, University of Virginia, Charlottesville, VAProgram for T-Cell Lymphoma Research, University of Virginia, Charlottesville, VABiogen, Cambridge, MAMassachusetts Institute of Technology, Cambridge, MAMassachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; Correspondence: Salvia Jain, Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114-2696;Abstract: Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a ''novel'' single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.http://www.sciencedirect.com/science/article/pii/S2473952924006402 |
| spellingShingle | Jessy Xinyi Han Min Jung Koh Leora Boussi Mark Sorial Sean M. McCabe Luke Peng Shambhavi Singh Ijeoma Julie Eche-Ugwu Judith Gabler Maria J. Fernandez Turizo Caroline T. MacVicar Aditya Garg Alexander Disciullo Kusha Chopra Alexandra Lenart Emmanuel Nwodo Jeffrey Barnes Min Ji Koh Eliana Miranda Carlos Chiattone Robert Stuver Steven M. Horwitz Mwanasha Merrill Eric Jacobsen Martina Manni Monica Civallero Tetiana Skrypets Athina Lymboussaki Massimo Federico Yuri Kim Jin Seok Kim Jae Yong Cho Thomas Eipe Tanuja Shet Epari Sridhar Alok Shetty Saswata Saha Hasmukh Jain Manju Sengar Carrie Van Der Weyden Henry Miles Prince Ramzi Hamouche Tinatin Murdashvili Francine Foss Marianna Gentilini Beatrice Casadei Pier Luigi Zinzani Takeshi Okatani Noriaki Yoshida Sang Eun Yoon Won-Seog Kim Girisha Panchoo Zainab Mohamed Estelle Verburgh Jackielyn Cuenca Alturas Mubarak Al-Mansour Josie Ford Maria Elena Cabrera Amy Ku Govind Bhagat Helen Ma Ahmed Sawas Khyati Maulik Kariya Makoto Iwasaki Forum Bhanushali Owen A. O’Connor Enrica Marchi Changyu Shen Devavrat Shah Salvia Jain Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium Blood Advances |
| title | Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| title_full | Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| title_fullStr | Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| title_full_unstemmed | Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| title_short | Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| title_sort | global outcomes and prognosis for relapsed refractory mature t cell and nk cell lymphomas results from the petal consortium |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924006402 |
| work_keys_str_mv | AT jessyxinyihan globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT minjungkoh globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT leoraboussi globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT marksorial globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT seanmmccabe globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT lukepeng globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT shambhavisingh globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT ijeomajulieecheugwu globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT judithgabler globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT mariajfernandezturizo globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT carolinetmacvicar globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT adityagarg globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT alexanderdisciullo globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT kushachopra globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT alexandralenart globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT emmanuelnwodo globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT jeffreybarnes globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT minjikoh globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT elianamiranda globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT carloschiattone globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT robertstuver globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT stevenmhorwitz globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT mwanashamerrill globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT ericjacobsen globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT martinamanni globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT monicacivallero globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT tetianaskrypets globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT athinalymboussaki globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT massimofederico globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT yurikim globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT jinseokkim globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT jaeyongcho globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT thomaseipe globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT tanujashet globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT eparisridhar globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT alokshetty globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT saswatasaha globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT hasmukhjain globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT manjusengar globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT carrievanderweyden globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT henrymilesprince globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT ramzihamouche globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT tinatinmurdashvili globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT francinefoss globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT mariannagentilini globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT beatricecasadei globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT pierluigizinzani globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT takeshiokatani globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT noriakiyoshida globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT sangeunyoon globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT wonseogkim globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT girishapanchoo globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT zainabmohamed globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT estelleverburgh globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT jackielyncuencaalturas globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT mubarakalmansour globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT josieford globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT mariaelenacabrera globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT amyku globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT govindbhagat globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT helenma globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT ahmedsawas globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT khyatimaulikkariya globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT makotoiwasaki globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT forumbhanushali globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT owenaoconnor globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT enricamarchi globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT changyushen globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT devavratshah globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium AT salviajain globaloutcomesandprognosisforrelapsedrefractorymaturetcellandnkcelllymphomasresultsfromthepetalconsortium |